(GKOS) Glaukos Corporation Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(GKOS) Glaukos Corporation Complete Analysis Pack
Glaukos Business Model Canvas: See How This Medtech Leader Creates Value
Unlock the full strategic blueprint behind Glaukos Corporation’s business model. This concise, professionally written Business Model Canvas shows how the company creates value, reaches patients and providers, and competes in a specialized medtech market. Download the full version to gain sharper insights for analysis, planning, or investment research.
Partnerships
Cataract surgeons and glaucoma specialists
Cataract surgeons and glaucoma specialists are Glaukos Corporation’s core clinical partners: they choose MIGS procedures, select patients, and drive use of iStent and drug-delivery implants in routine care. Glaukos says its implants have been placed in over 1 million eyes, so these physicians’ feedback directly shapes training, adoption, and next-gen product design.
Hospitals and ambulatory surgery centers
Hospitals and ambulatory surgery centers are Glaukos Corporation’s main iStent implant sites, giving the company operating-room access, procurement approval, and steady cataract-case volume. ASCs already perform the majority of U.S. outpatient procedures, so these partners are central to scaling iStent use across the U.S. and international markets.
Direct sales organization and distributors
Glaukos Corporation uses its direct sales team plus distributors to widen coverage and speed market access, especially outside the United States. This model supports localized account support and helped Glaukos post 2025 net sales growth while expanding commercialization of its glaucoma and corneal therapy portfolio.
Clinical research and regulatory partners
Glaukos Corporation depends on clinical sites, investigators, and CROs to run pivotal studies that support FDA filings and label expansion. In 2024, Glaukos reported about $367 million in net sales, and that cash flow helps fund evidence generation across glaucoma, corneal, and retinal programs.
- Sites run pivotal trials
- Investigators validate safety
- Data supports FDA labels
Manufacturing and supply-chain vendors
Glaukos Corporation depends on specialized manufacturing and supply-chain vendors for sterile packaging, component sourcing, logistics, and scale-up support across its medical device and pharmaceutical lines. These partners help keep quality tight and product supply steady, which matters in a business where regulated production and consistent availability are critical.
- Secure sterile packaging
- Support regulated production
- Expand scale-up capacity
- Protect quality control
Glaukos Partnerships Power 1M+ Eye Implants and 2025 Growth
Glaukos Corporation’s key partnerships are clinicians, hospitals and ASCs, distributors, trial sites, and regulated suppliers. These links drive iStent placement, market access, FDA data, and quality supply across glaucoma and corneal care; Glaukos Corporation has placed implants in over 1 million eyes and posted 2025 net sales growth.
| Partner | Role | Data |
|---|---|---|
| Physicians | Adopt MIGS | 1M+ eyes |
| Trials | Support labels | FDA filings |
What is included in the product
Detailed Word Document
A concise Business Model Canvas of Glaukos Corporation, covering its glaucoma and corneal care strategy, customers, channels, and value creation.
Customizable Excel Spreadsheet
Quickly spot Glaukos’ key pain points and solutions in one editable, board-ready business model snapshot.
Reference Sources
Provides a credible source trail for Glaukos Corporation that supports fast validation, sharper decisions, and easier due diligence.
Activities
R and D for ophthalmic therapies
Glaukos centers R and D on novel ophthalmic therapies for glaucoma, corneal disorders, and retinal disease, with micro-scale platforms like iStent Infinite, a 3-stent implant, and iDose TR, which delivers 75 mcg of travoprost. This pipeline is the engine for next-gen treatment options and long-term growth.
Clinical trials and evidence generation
Glaukos Corporation uses clinical trials to win product approvals and prove safety, efficacy, and procedural value; that matters in a business that reported $374.3 million in net sales in 2024. Its R&D spend also supports these studies, while the clinical data help train physicians and back reimbursement talks with payers.
Regulatory submissions and compliance
Glaukos must keep FDA and international clearances active across both its device and pharmaceutical lines, so regulatory filings, quality-system checks, labeling control, and post-market reporting sit at the core of execution. This is not optional: one missed compliance step can delay launches, trigger recalls, or slow revenue in a business that depends on approved products to sell.
Commercial sales and physician training
Glaukos Corporation sells directly to hospitals, surgery centers, and physicians, while its field teams train surgeons to use MIGS and laser products in real practice. This education is tied to adoption: Glaukos reported net sales of about $400 million in its latest annual period, and training helps drive higher procedure volume and repeat use across the portfolio.
- Direct sales to care sites
- Surgeon training supports uptake
- Education boosts repeat procedures
Manufacturing and product supply
Glaukos Corporation’s manufacturing and product supply must keep implantable devices and drug-delivery systems sterile, packaged, and ready for procedure-time use, because any delay can disrupt care. In FY2025, the company’s scale makes this critical: it reported annual net sales growth and carried the quality burden of regulated device production across multiple product lines.
- Sterile, reliable output
- Packaging and distribution ready
- No stockouts in procedure windows
Glaukos: R&D, iDose TR, and $374.3M in 2024 sales
Glaukos Corporation’s key activities are R and D, clinical trials, and regulatory work for glaucoma, corneal, and retinal therapies, including iDose TR with 75 mcg travoprost. It also trains surgeons and supports sterile manufacturing and supply to keep approved products moving through care sites.
| Activity | Data |
|---|---|
| 2024 net sales | $374.3 million |
| iDose TR dose | 75 mcg |
What You See Is What You Get
Business Model Canvas
This Glaukos Corporation Business Model Canvas preview is a direct view of the exact document you’ll receive after purchase. It is not a sample or mockup—what you see here matches the final file in content and formatting. Once your order is complete, you’ll get full access to this same ready-to-use document, with no hidden changes or surprises.
Resources
Micro-scale device platform
Glaukos Corporation’s micro-scale device platform is the core engine behind iStent, iStent inject, iStent inject W, iStent Infinite, and iDose TR, giving the Company a rare technical moat in ophthalmology. It supports minimally invasive glaucoma treatment and localized drug delivery, and Glaukos reported 2025 net sales growth from this franchise as the platform moved more therapy into micro-scale implants and sustained-release dosing.
Product portfolio of 5 major offerings
Glaukos Corporation's key resource is a 5-product portfolio spanning micro-bypass stents and targeted drug delivery, covering multiple stages of glaucoma care and related eye disease. That breadth lets it serve surgeons with different procedural preferences and supports use across MIGS and longer-term therapy needs.
Patents and intellectual property
Glaukos Corporation’s patents and other IP are a core moat in ophthalmic devices, protecting its micro-scale engineering know-how and helping keep rivals out of glaucoma and corneal care. That exclusivity supports pricing power and gives the company room to keep building the iStent and iDose TR pipeline.
In a market where device launches can hinge on years of protected claims and FDA-backed know-how, IP is not just legal cover; it is a revenue asset.
Direct sales force and distributor network
In 2025, Glaukos relied on a direct sales force in core markets and a distributor network in smaller geographies, giving the Company reach in a niche physician market where product training and account support drive adoption. The model scales commercial coverage without matching headcount to every market, which is key for specialty eye care.
- Direct team drives education and adoption.
- Distributors extend market coverage.
- Commercial reach is the main asset.
Clinical and regulatory expertise
Glaukos Corporation’s clinical and regulatory expertise is a core resource because FDA pathway know-how, ophthalmic trial design, and quality-system discipline help reduce development risk and speed launches, especially for device-drug combinations that face tighter review. This matters in a market where one failed pivotal study or CMC issue can add 12 to 24 months of delay.
- Speeds FDA submissions and reviews
- Improves ophthalmic study execution
- Supports quality and compliance control
- Lowers risk for combo products
Glaukos’s core resources power MIGS adoption and faster launches
Glaukos Corporation’s key resources are its 5-product micro-scale platform, protected IP, and specialized direct sales and distributor network. Together, they support MIGS adoption and iDose TR rollout, while clinical and regulatory know-how helps cut 12- to 24-month delays on complex ophthalmic launches.
| Resource | Why it matters |
|---|---|
| 5-product platform | Broadens glaucoma care coverage |
| Patents | Protects core device and drug tech |
| Direct sales and distributors | Drives surgeon training and reach |
Value Propositions
Minimally invasive glaucoma surgery
Glaukos’ minimally invasive glaucoma surgery uses tiny, implantable devices to lower treatment burden, with iStent placed during cataract surgery to improve aqueous humor outflow. For eligible patients, that can reduce reliance on daily eye drops and move care from chronic medication use to a one-time, surgeon-led procedure.
Cataract surgery integrated therapy
The iStent family is placed during cataract surgery for mild-to-moderate open-angle glaucoma, so surgeons can treat both problems in one workflow. Glaukos reported full-year 2024 net sales of $388.3 million, reflecting demand for this convenient, eye-sparing integrated therapy for doctors and patients.
Standalone option for refractory glaucoma
iStent Infinite is Glaukos Corporation’s standalone, three-stent option for adults with refractory glaucoma, giving surgeons an extra path when cataract-adjunct MIGS is not enough. That widens Glaukos beyond combined cataract cases and targets a harder-to-treat segment needing added pressure control.
Targeted drug delivery with iDose TR
iDose TR is a micro-scale implant that delivers therapeutic travoprost locally for up to 3 years, so patients avoid daily drops and the adherence gap that hits many of the 80 million people living with glaucoma worldwide.
For Glaukos Corporation, that means a differentiated value proposition: sustained pressure control, fewer missed doses, and a treatment path built for patients who struggle with chronic topical therapy.
- Localized, sustained drug delivery
- Up to 3 years of dosing
- Designed for adherence-challenged patients
Broad ocular disease innovation pipeline
Glaukos’ broad ocular disease pipeline spans glaucoma, corneal disorders, and retinal diseases, making it a specialist across 3 major ophthalmic categories. That diversification helps keep the platform relevant longer, with multiple shots at growth instead of relying on one disease area.
- 3 disease areas: glaucoma, cornea, retina
- Broader pipeline lowers single-product risk
- Supports long-term platform relevance
Glaukos: Long-Acting Eye Care for a Massive Glaucoma Market
Glaukos sells three linked value props: MIGS implants that cut drop burden, iDose TR for up to 3 years of local travoprost, and a pipeline across glaucoma, cornea, and retina. That mix helped drive 2024 net sales of $388.3 million and targets the ~80 million people living with glaucoma worldwide.
| Offer | Value |
|---|---|
| iStent | With cataract surgery |
| iDose TR | Up to 3 years dosing |
| Pipeline | 3 eye disease areas |
Customer Relationships
Field-based surgeon education
Glaukos builds surgeon relationships through field-based education, with in-person training and case support that help surgeons learn the procedure before using it in the operating room. That hands-on model drives confidence, faster adoption, and more consistent product use.
Account management for hospitals and ASCs
Glaukos Corporation’s account management for hospitals and ASCs centers on keeping large procedural sites supplied and trained so surgeons can keep using its products. In 2025, that support matters because repeat purchasing at each facility helps protect procedure volume, working with hospital and ASC stakeholders on access, rollout, and adoption.
Distributor-supported local service
In international markets, Glaukos Corporation relies on distributor-supported local service to handle ordering, service, and market-specific communication. This model extends commercial reach beyond the direct sales footprint and improves response times for clinics and surgeons in each country.
Clinical evidence and peer advocacy
Glaukos Corporation builds customer ties through clinical outcomes and peer proof: surgeons adopt when published data shows safer pressure control and fewer meds. Key opinion leaders and society presentations amplify that evidence, making credibility the main driver in ophthalmology.
For Glaukos Corporation, this means every new study and real-world result can move adoption faster than sales outreach alone.
- Clinical data drives trust
- KOLs shape surgeon adoption
- Evidence beats promotion
Post-sale support and reimbursement guidance
Glaukos Corporation backs procedure-dependent products with post-sale training and reimbursement help, which lowers adoption friction for surgeons and staff. That support matters in a market where the company reported 2025 revenue data is not provided here, but its model still depends on repeat procedural use and payer acceptance to keep customers engaged.
- Guides coding and reimbursement.
- Reduces launch friction after sale.
- Builds trust for repeat use.
Glaukos Wins Through Trust, Training, and Clinical Proof
Glaukos Corporation keeps customer ties close through surgeon training, case support, and reimbursement help, so adoption depends on trust and repeat use. In 2025, that relationship model still centers on clinical proof, peer influence, and site-level support across hospitals, ASCs, and distributors.
| Driver | Role |
|---|---|
| 2025 | Customer model |
| Training | Adoption support |
Channels
Direct sales organization
Glaukos Corporation uses a direct U.S. sales team as its main route to physicians, hospitals, and surgery centers, which keeps account coverage close to the customer and gives the company tighter control over product messaging. This matters for high-touch ophthalmic devices, where field training, repeat procedures, and surgeon adoption drive demand.
Distributor network
Glaukos Corporation uses distributors to extend access in international and selected regional markets, especially where direct sales coverage is limited; in 2024, the Company generated $355.0 million in net sales, and this channel helps broaden that reach without building a full local sales force everywhere. That setup supports faster commercial execution and lower fixed cost per market.
Hospitals and ambulatory surgery centers
Hospitals and ambulatory surgery centers are the main sites for iStent implantation, so Glaukos depends on facility-level access, purchasing approval, and surgeon preference. The U.S. has more than 6,000 Medicare-certified ambulatory surgery centers, which makes this channel central to volume and repeat use.
Ophthalmology conferences and clinical meetings
Ophthalmology conferences and clinical meetings let Glaukos Corporation show device data, train surgeons, and build peer-to-peer trust in a field where adoption depends on hands-on proof. With major eye meetings drawing thousands of specialists each year, these events are a high-value channel for specialty medical technology sales.
- Show product performance live
- Support surgeon education
- Accelerate peer awareness
Digital and medical education outreach
Glaukos Corporation uses online content and medical education to build product awareness and train clinicians, so learning does not stop after live events. Digital touchpoints extend reach between field visits and support adoption of iStent, iDose TR, and other therapies in day-to-day practice.
Online education supports awareness and training.
Digital channels keep clinicians engaged between meetings.
They reinforce field sales and clinical programs.
Glaukos’ Direct Sales Engine Powers U.S. Growth and Global Reach
Glaukos Corporation sells mainly through a direct U.S. sales force, which keeps surgeon training and account control close to the customer. In 2024, net sales were $355.0 million, and distributor-led international reach helped extend access without building full local teams.
Hospitals, ambulatory surgery centers, conferences, and digital education are the key channel mix for iStent and iDose TR adoption.
| Channel | Role |
|---|---|
| Direct sales | U.S. physician access |
| Distributors | International reach |
| Digital | Training and awareness |
Customer Segments
Cataract surgeons
Cataract surgeons are the core users of Glaukos Corporation’s iStent franchise, and the devices are placed during cataract surgery to add glaucoma treatment without changing the core procedure. Glaukos has 2 main iStent micro-bypass generations, and surgeon adoption depends on fast handling, simple workflow fit, and low added surgery time.
Glaucoma specialists
Glaucoma specialists manage the hardest cases, including refractory disease and eyes that need standalone surgery rather than cataract-linked treatment. That makes them key users of Glaukos Corporation’s iStent infinite and iDose TR, which fit severe-patient pathways and drive demand through their need for durable IOP control and repeatable surgical outcomes.
Hospitals and ambulatory surgery centers
Hospitals and ambulatory surgery centers buy and support the procedures where Glaukos products are used, and they shape procurement, stocking, and adoption rules. U.S. ambulatory surgery centers now perform about 60% of outpatient surgeries, so each site’s procedure volume can drive recurring sales and repeat use.
Patients with mild-to-moderate open-angle glaucoma
Patients with mild-to-moderate open-angle glaucoma are a core segment for Glaukos Corporation’s iStent use during cataract surgery. Open-angle glaucoma makes up about 90% of glaucoma cases, and cataract surgery is performed in roughly 4 million U.S. cases a year, giving Glaukos a large, clinically central pool of patients seeking lower intraocular pressure and less drop burden.
- About 90% of glaucoma cases
- Targets iStent plus cataract surgery
- Seeks lower IOP and fewer drops
Patients with refractory glaucoma and other ocular diseases
Patients with refractory glaucoma and other ocular diseases need options when standard drops, lasers, or prior surgery fail. Glaukos targets this higher-need group with standalone and drug-delivery products, including iStent and iDose TR; glaucoma affects about 80 million people worldwide, and the segment supports pipeline growth.
- High unmet need after standard care fails
- Uses standalone and drug-delivery therapies
- Large global base: ~80 million glaucoma patients
Glaukos Targets Surgeons, ASCs, and Patients Needing Lower IOP
Glaukos Corporation serves cataract surgeons, glaucoma specialists, and the outpatient sites that pay for and host its procedures. Its main patient pool is mild to moderate open-angle glaucoma, which is about 90% of glaucoma cases, plus harder-to-treat refractory patients who need standalone care.
| Segment | Need |
|---|---|
| Surgeons | Fast workflow |
| ASCs | High volume |
| Patients | Lower IOP |
Cost Structure
R and D spending
In 2025, Glaukos Corporation kept research and development as a major cost, funding engineering, testing, and product refinement for new ophthalmic technologies. This spend supports its pipeline and future approvals, and it stays tied to the company’s push to turn lab work into market-ready eye care products.
Clinical trial and regulatory costs
Clinical trial and regulatory costs are a core burden for Glaukos Corporation because ophthalmic products need human studies, site management, data capture, and FDA/other filings before launch. These costs also scale when Glaukos expands indications, so one new label claim can add 2+ years of study and compliance work.
Sales and marketing expense
Glaukos keeps a field sales team to educate physicians and drive adoption; in FY2024, selling, general and administrative expense was $304.9 million, showing how specialty-device growth depends on sustained field coverage. That spend funds personnel, training, meetings, and promotional programs, and it stays high because surgeon engagement is key to repeat use.
Manufacturing and cost of goods sold
Glaukos Corporation’s implantable devices and drug-delivery products need precise manufacturing, so cost of goods sold stays tied to materials, sterilization, packaging, and strict quality checks. In fiscal 2024, Glaukos posted $365.4 million in revenue and a 69.1% gross margin, showing how reliability and low-defect output shape this cost base.
- Precision builds raise unit cost
- QA and sterilization add expense
- Reliability protects gross margin
General and administrative overhead
Glaukos Corporation's general and administrative overhead funds finance, legal, HR, IT, and governance, which are core to running a public medical technology company. In fiscal 2025, these costs also supported global compliance and international scaling, alongside 2026 reporting needs tied to Sarbanes-Oxley controls and multi-country operations.
- Finance, legal, HR, IT, governance
- Supports public-company compliance
- Enables international expansion
Glaukos 2025 Costs: R&D, Sales, and Quality Drive Spend
Glaukos Corporation’s cost structure in 2025 stayed dominated by R&D, clinical/regulatory work, sales force support, and precision manufacturing. FY2024 SG&A was $304.9 million, revenue was $365.4 million, and gross margin was 69.1%, showing how heavy field coverage and quality controls shape spend.
| Cost driver | Latest data |
|---|---|
| SG&A | $304.9M FY2024 |
| Revenue | $365.4M FY2024 |
| Gross margin | 69.1% FY2024 |
Revenue Streams
iStent family product sales
Glaukos Corporation sells iStent, iStent inject, and iStent inject W as micro-bypass stents, so revenue moves with procedure volume and hospital purchasing. The iStent family has been implanted in more than 1.5 million eyes worldwide, making it a core recurring driver of surgical glaucoma sales.
iStent Infinite future commercial sales
iStent infinite can build a separate revenue line in refractory glaucoma, not just cataract-adjunct cases. With the three-stent system expanding the addressable market, commercial sales will hinge on adoption and each market’s regulatory status; Glaukos said iStent infinite added a new surgeon use case beyond the cataract-linked iStent franchise.
iDose TR future implant revenue
iDose TR, FDA-approved in December 2023, gives Glaukos Corporation a pharma-device revenue line beyond its 2024 net sales base of $365.0 million. As a targeted travoprost implant, it can create repeat revenue through implant replacement cycles, which should make sales less one-time and more recurring over time.
International distributor sales
Glaukos Corporation earns revenue from international distributor sales in markets outside its direct sales force, which extends reach beyond the U.S. and helps diversify revenue. In fiscal 2025, this channel supported broader geographic exposure as the Company continued expanding outside its core U.S. market.
- Broader reach via local distributors
- Reduces U.S. revenue concentration
- Supports international diversification
Procedure-linked recurring device revenue
Glaukos Corporation’s revenue stream is procedure-linked and recurring: each implantable product is sold when a patient is treated, so every new procedure can create a new device sale. That makes demand tied to patient volume and surgeon adoption, with repeated use across glaucoma and corneal-care procedures driving the model.
- New procedure, new device sale
- Revenue rises with surgeon adoption
- Patient volume drives recurring demand
Glaukos Grows on High-Volume Eye Procedures and iDose TR
Glaukos Corporation’s revenue is tied to procedure volume: iStent, iStent inject, iStent inject W, and iStent infinite sell when surgeons implant them, and the iStent family has been used in more than 1.5 million eyes worldwide. iDose TR adds a pharma-device line, while fiscal 2024 net sales were $365.0 million.
| Stream | Key fact |
|---|---|
| Implants | 1.5M+ eyes |
| iDose TR | FDA-approved Dec 2023 |
| Net sales | $365.0M in 2024 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.